Methoden vergelijken
Bekijk de geselecteerde methoden naast elkaar; rijen die verschillen zijn gemarkeerd.
| Internationale Prostaat Symptoom Score× | Patient Health Questionnaire-2× | |
|---|---|---|
| Vakgebied | Gezondheidszorg | Gezondheidszorg |
| Familie | Process / pipeline | Process / pipeline |
| Jaar van ontstaan≠ | 1992 | 2003 |
| Grondlegger≠ | American Urological Association (AUA) and International Prostate Symptom Score Committee | Kurt Kroenke, Robert L. Spitzer, and Janet B. Williams |
| Type≠ | Eight-item symptom severity questionnaire | Two-item depression screening instrument |
| Oorspronkelijke bron≠ | Barry, M. J., Fowler, F. J., O'Leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., & Mebust, W. K. (1992). The American Urological Association symptom index for benign prostatic hyperplasia. Journal of Urology, 148(5), 1549-1557. DOI ↗ | Kroenke, K., Spitzer, R. L., & Williams, J. B. (2003). The Patient Health Questionnaire-2: validity of a two-item depression screener. Medical Care, 41(11), 1284-1292. DOI ↗ |
| Aliassen | IPSS, AUA Symptom Index | PHQ-2, Patient Health Questionnaire |
| Verwant | 3 | 3 |
| Samenvatting≠ | The International Prostate Symptom Score (IPSS) is a validated seven-item self-report instrument adopted by the World Health Organization and American Urological Association to measure the severity of lower urinary tract symptoms (LUTS) in men with suspected benign prostatic hyperplasia (BPH). The IPSS comprises items assessing frequency of nocturia, urgency, weak stream, hesitancy, intermittency, and incomplete emptying over the past month. It is the gold standard measure for BPH symptom severity assessment in clinical practice and research. | The Patient Health Questionnaire-2 (PHQ-2) is an ultra-brief, validated two-item screening instrument developed by Kroenke and colleagues in 2003 to identify major depression in primary care and medical populations. The PHQ-2 assesses the two cardinal symptoms of depression (depressed mood and anhedonia) over the past two weeks using a 0-3 frequency scale. It is the shortest validated depression screening tool enabling routine use in time-constrained clinical settings. |
| ScholarGateGegevensset ↗ |
|
|